Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 1889-1896

  Lu, Liangjun ^a   Mo, Hongmei ^b   Pilot Matias, Tami J ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 782759; BENZOTHIADIAZINE DERIVATIVE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ALLELE; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; EVOLUTION; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; RNA ISOLATION; VIRUS DETECTION;

BENZOTHIADIAZINES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; EVOLUTION, MOLECULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; REPLICON; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 34250166157     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01004-06     Document Type: Article

References (32)

1. Cohen, J. 1999. The scientific challenge of hepatitis C. Science 285:26-30.
2. Domingo, E., L. Menendez-Arias, and J. J. Holland. 1997. RNA virus fitness. Rev. Med. Virol. 7:87-96.
3. Grahovac, B., J. Bingulac-Popovic, B. Vucelic, I. Hrstic, R. Ostojic, V. Drazic, M. Balija, and D. Grgicevic. 2001. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C. J. Clin. Virol. 20:85-89.
4. Herrmann, E., J. H. Lee, G. Marinos, M. Modi, and S. Zeuzem. 2003. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351-1358.
5. Herrmann, E., and S. Zeuzem. 2006. The kinetics of hepatitis C virus. Eur. J. Gastroenterol. Hepatol. 18:339-342.
6. Lavanchy, D., and B. McMahon. 2000. Worldwide prevalence and prevention of hepatitis C, p. 185-202. In J. T. Liang and J. H. Hoofnagle (ed.), Hepatitis C. Academic Press, Inc., San Diego, CA.
7. Lech, W. J., G. Wang, Y. L. Yang, Y. Chee, K. Dorman, D. McCrae, L. C. Lazzeroni, J. W. Erickson, J. S. Sinsheimer, and A. H. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
8. Le Pogam, S., H. Kang, S. F. Harris, V. Leveque, A. M. Giannetti, S. Ali, W. R. Jiang, S. Rajyaguru, G. Tavares, C. Oshiro, T. Hendricks, K. Klumpp, J. Symons, M. F. Browner, N. Cammack, and I. Najera. 2006. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80:6146-6154.
9. Lin, C., K. Lin, Y. P. Luong, B. G. Rao, Y. Y. Wei, D. L. Brennan, J. R. Fulghum, H. M. Hsiao, S. Ma, J. P. Maxwell, K. M. Cottrell, R. B. Perni, C. A. Gates, and A. D. Kwong. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279:17508- 17514.
10. Loubser, S., P. Balfe, G. Sherman, S. Hammer, L. Kuhn, and L. Morris. 2006. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20:995-1002.
11. Lu, L., T. Pilot-Matias, K. D. Stewart, J. Randolph, R. Pithawalla, W. He, P. Huang, L. Klein, H. Mo, and A. Molla. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266.
12. Lu, L., P. Krishman, R. Pithawalla, T. Dekhtyar, T. Ng, W. He, T. Pilot-Matias, D. Larson, T. Bosse, R. Wagner, D. Kempf, A. Molla, and H. Mo. 2006. Selection and characterization of hepatitis C virus replicons resistant to a potent polymerase inhibitor A-837093. Hepatology. 44(Suppl. 1):351A.
13. Martell, M., J. I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, J. Guardia, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66:3225-3229.
14. Metzner, K. J., S. Bonhoeffer, M. Fischer, R. Karanicolas, K. Allers, B. Joos, R. Weber, B. Hirschel, L. G. Kostrikis, H. F. Gunthard, et al. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188:1433-1443.
15. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
16. Mo, H., L. Lu, T. Pilot-Matias, R. Pithawalla, R. Mondal, S. Masse, T. Dekhtyar, T. Ng, G. Koev, V. Stoll, K. D. Stewart, J. Pratt, P. Donner, T. Rockway, C. Maring, and A. Molla. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49:4305-1314.
17. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
18. Nguyen, T. T., A. T. Gates, L. L. Gutshall, V. K. Johnston, B. Gu, K. J. Duffy, and R. T. Sarisky. 2003. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47:3525-3530.
19. Palmer, S., V. Boltz, F. Maldarelli, M. Kearney, E. K. Halvas, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710.
20. Paolucci, S., F. Baldanti, G. Campanini, M. Zavattoni, E. Cattaneo, L. Dossena, and G. Gerna. 2001. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J. Med. Virol. 65:207-217.
21. Pawlotsky, J. M. 2000. Hepatitis C virus resistance to antiviral therapy. Hepatology 32:889-896.
22. Pawlotsky, J. M. 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43:S207-S220.
23. Reesink, H. W., S. Zeuzem, C. J. Weegink, N. Forestier, A. Van Vliet, J. Van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, and P. L. M. Jansen. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
24. Ribeiro, R. M., and S. Bonhoeffer. 2000. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97:7681-7686.
25. Sarrazin, C., T. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, C. Lin, T. Grossman, S. Purdy, C. Weegink, H. Reesink, S. Zeuzem, and A. Kwong. 2005. Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 42(Suppl. 1):537A.
26. Sumpter, R., Jr., C. Wang, E. Foy, Y. M. Loo, and M. Gale, Jr. 2004. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J. Virol. 78:11591-11604.
27. Tomei, L., S. Altamura, L. Bartholomew, M. Bisbocci, C. Bailey, M. Bosserman, A. Cellucci, E. Forte, I. Incitti, L. Orsatti, U. Koch, R. De Francesco, D. B. Olsen, S. S. Carroll, and G. Migliaccio. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946.
28. Tong, X., R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B. A. Malcolm. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir. Res. 70:28-38.
29. Tong, X., Z. Guo, J. Wright-Minogue, E. Xia, A. Prongay, V. Madison, P. Qiu, S. Venkatraman, F. Velazquez, F. G. Njoroge, and B. A. Malcolm. 2006. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 7:1353-1361.
30. Trozzi, C., L. Bartholomew, A. Ceccacci, G. Biasiol, L. Pacini, S. Altamura, F. Narjes, E. Muraglia, G. Paonessa, U. Koch, R. De Francesco, C. Steinkuhler, and G. Migliaccio. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679.
31. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16.
32. Wright, M., J. Main, and H. C. Thomas. 2001. Treatment of chronic viral hepatitis. Antivir. Chem. Chemother. 12:201-212.